Search our team at AdventHealth Research Institute
-
NCT05761171
AALL2121: A Phase 2 Study of SNDX-5613 in Combination with Chemotherapy for Patients with Relapsed or Refractory KMT2A-Rearranged Infant Leukemia
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe overall goal of this study is to determine the safety and best dose of the drug SNDX-5613 for young children when given in combination with chemotherapy, and to see if this treatment will improve...
-
NCT05602194
A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Pediatric Research and Clinical TrialsResearch Location: Orlando, FloridaThe overall goal of this study is to determine whether adding levocarnitine to standard of care ALL treatment will reduce the chances of developing severe liver damage from asparaginase chemotherapy.
-
NCT05918913
SNDX-5613-0707: Expanded Access Program for SNDX-5613 in Patients with Relapsed/Refractory Acute Leukemias with Genetic Alterations Associated with HOXA Overexpression
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe therapy that will be receive involves being given the drug SNDX-5613 to treat Relapsed/Refractory acute leukemias, including those harboring an KMT2Ar Gene Rearrangement, Nucleophosmin 1 (NPM1m)...
-
NCT02981628
A Phase 2 Study of INotuzumab Ozogamicin (NSC# 772518, IND #133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe overall goal of this study is to find out what effect, good and/or bad, the drug inotuzumab ozogamicin has on children and young adults with relapsed or refractory B-ALL.
-
NCT02521493
CIRB/COG AAML1531 Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
This study is not currently enrolling.Associated Conditions: Pediatric CancerResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe overall goals of this study are to: To find out if subjects with standard risk DS AML can be treated with less treatment and still have successful outcomes. To find out if subjects with high risk...
-
NCT02723994
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
This study is not currently enrolling.Associated Conditions: LeukemiaResearch Area: Pediatric Research and Clinical TrialsThe overall goal of this study are to: Part 1 - Find the best dose of ruxolitinib to use with standard chemotherapy in children, adolescents, and young adults with HR B-ALL; Part 2 - Find out if the...
-
NCT06226571
A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A (KMT2A/MLL), Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaThe purpose of this study is to find the best dose of revumenib taken with other cancer drugs, known as chemotherapy, and to find out what side effects happen after you take this study drug. It will...
-
NCT0645646
A Phase II multicenter open-label trial of tagraxofusp (Tag) in combination with venetoclax and azacitidine (Ven/Aza) in adults with previously untreated CD123+ acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaOverall, the goal of this research study is to determine if tagraxofusp (Tag) in combination with venetoclax (Ven) and azacitidine (Aza) can safely treat cancer in patients who have not received...
-
NCT06456463
A Phase II multicenter open-label trial of tagraxofusp (Tag) in combination with venetoclax and azacitidine (Ven/Aza) in adults with previously untreated CD123+ acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.
This study is not currently enrolling.Associated Conditions: LeukemiaResearch Area: Clinical Cancer Research -
NCT03959085
A Phase 3 Randomized Trial of INotuzumab Ozogamicin (IND#: 133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Clinical Cancer ResearchDisseminated B-Cell Lymphoblastic Lymphoma (B-LLy): The overall goal of this study is to determine the outcomes of subjects with disseminated B-LLy receiving High Risk B-cell Acute Lymphoblastic...
-
NCT04836390
A Phase II Pilot Study of Donor-Derived Ex-VivoExpanded Natural Killer Cell Infusions in Childrenand Young Adults with High-Risk Acute Myeloid Leukemia Receiving Myeloablative HLA Haploidentical Hematopoietic Cell Transplant: A Multicenter Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) Study (EXCEL Trial) PTCTC CT2001.
This study is currently enrolling.Associated Conditions: LeukemiaResearch Area: Clinical Cancer ResearchResearch Location: Orlando, FloridaParticipants will be invited to join this study if they have a blood disease called acute myeloid leukemia (AML) and it has been decided that they need a transplant as part of their treatment plan....
-
NCT05457556
A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic Syndrome (MDS)
This study is currently enrolling.Associated Conditions: Cancer, Multiple Tumor TypesResearch Area: Pediatric Research and Clinical TrialsResearch Location: Orlando, FloridaYou are being asked to take part in this research study because you have been diagnosed with acute leukemia or myelodysplastic syndrome (MDS).